Alliance Pharma PLC Block Listing Six Monthly Return
2024年7月2日 - 7:00PM
RNS Regulatory News
RNS Number : 8098U
Alliance Pharma PLC
02 July 2024
|
For immediate release
|
02 July
2024
|
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly
Return
|
Name of applicant:
|
ALLIANCE PHARMA PLC
|
|
Names of schemes:
|
a) The
Alliance Pharma plc Approved Share Option Plan 2005
b) The Alliance
Pharma plc Share Option Plan 2006
c) The
Alliance Pharma plc Company Share Option Plan 2015
d) The Alliance
Pharma plc Long-Term Incentive Plan 2019
|
|
Period of return:
|
From:
|
28 December 2023
|
To:
|
28 June 2024
|
|
Number of securities originally
admitted at date of admission:
|
25,000,000 ordinary shares of 1p
each
28 June 2017
|
|
Balance of unallotted securities
under schemes from previous return:
|
a)
57,922
b)
2,473,507
c)
9,572,622
d)
1,115,498
|
|
Plus:
The amount by which the block schemes have been
increased since the date of the last return (if any increase has
been applied for):
|
a)
Nil
b) Nil
c)
Nil
d) Nil
|
|
Less:
Number of securities issued/allotted under
schemes during period:
|
a) 57,922
b) 30,496
c) Nil
d) 87,041
|
|
Equals:
Balance under schemes not yet issued/allotted at
end of period:
|
a) Nil
b)
2,443,011
c) 9,572,622
d)
1,028,457
|
|
|
|
|
|
|
Name of contact:
|
Chris Chrysanthou, Company
Secretary
|
|
Telephone number of
contact:
|
Tel. +44 (0)1249 705166
|
For
further information:
|
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
|
Head of Investor Relations: Cora
McCallum
|
+ 44
(0)1249 705168
|
|
ir@allianceph.com
|
|
|
|
|
|
Burson Buchanan
|
+ 44 (0)20 7466
5000
|
|
Mark Court / Sophie Wills
|
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
|
Nominated Adviser: Freddie Barnfield
/ Duncan Monteith / Sher Shah
|
|
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM:
APH) is a growing consumer healthcare
company. Our
purpose is to empower people to make a positive difference to their
health and wellbeing by making our trusted and proven brands
available around the world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands. For more information on
Alliance, please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRUUVKRSBUBRRR
Alliance Pharma (LSE:APH)
過去 株価チャート
から 11 2024 まで 12 2024
Alliance Pharma (LSE:APH)
過去 株価チャート
から 12 2023 まで 12 2024
